Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02057640 · ClinicalTrials.gov registry record · Phase 1

MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma

A Phase 1 study of Multiple Myeloma and Plasma Cell Myeloma, sponsored by Jason Valent.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
2
Study locations

NCT02057640 is a Phase 1 study of Multiple Myeloma and Plasma Cell Myeloma that has completed, run by Jason Valent. The registered enrollment target is 16 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02057640, a Phase 1 study of Multiple Myeloma and Plasma Cell Myeloma, has completed, sponsored by Jason Valent.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
2
Study locations

Study Summary

This study will look at the safety and tolerability of the new drug MLN9708 in combination with the existing drugs panobinostat and dexamethasone among patients with relapsed or refractory multiple myeloma. This study will also look at the response and clinical benefit of the treatment and the progression-free survival and overall survival of study participants.

Conditions Studied

Multiple Myeloma Plasma Cell Myeloma Kahler Disease Myelomatosis

Interventions

  • DRUG Dexamethasone
  • DRUG Panobinostat
  • DRUG MLN9708

Study Locations (2)

Ohio

  • University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland
  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2014-05-22
Est. Completion 2018-05-15
Phase Phase 1

Sponsor

Jason Valent

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02057640

The ClinicalTrials.gov registry entry for NCT02057640 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower). The listed sponsor is Jason Valent, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.

NCT02057640 reports 2 study locations spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT02057640 about?

NCT02057640 is a clinical study titled "MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma". This study will look at the safety and tolerability of the new drug MLN9708 in combination with the existing drugs panobinostat and dexamethasone among patients with relapsed or refractory multiple myeloma. This study will also look at the response and clinical benefit of the treatment and the progr...

What is the current status of trial NCT02057640?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2014-05-22. Estimated completion is 2018-05-15.

What conditions does trial NCT02057640 study?

This clinical trial studies the following conditions: Multiple Myeloma, Plasma Cell Myeloma, Kahler Disease, Myelomatosis.

What interventions are being tested in trial NCT02057640?

The interventions under investigation include: Dexamethasone (DRUG), Panobinostat (DRUG), MLN9708 (DRUG).

Who is sponsoring clinical trial NCT02057640?

This trial is sponsored by Jason Valent, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02057640 being conducted?

This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Plasma Cell Myeloma

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.